This company has been getting a lot of exposure in the buy-o-tech sektor. I have no idea what i'm doing but this looks like a winna 2 me.
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported...
SGMO will retrace slightly before its FDA approval, still trading above 100 EMA, MFI/RSI cooling off.
Note: This is not an investment advice but my opinion alone. Please feel free to comment. Correction almost done and that is my PT
bad data today was release that cause the trend to reverse would be looking for the that 38.2% fib retrace to next area of supply, see if demand picks up there or it will fall further.
one of martin shkreli's old picks (aka pharma bro) looks like it could be breaking up here look at the CS bo the cloud with volume and fisher support manage your risk gl hf xoxo snoop
Breakout to the upside from a Falling wedge.
2018-08-08 16:01:00 Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A
If this supply zone can be taken out by bulls, buyers will be starting to take control as supply zones are starting to get destroyed and demand zones are being created. If the trend does change, can start looking for long orders.
Sangamo Therapeutics, Inc. is a company that develops genomic therapies, using genome editing, gene therapy, gene regulation, and cell therapy. It's an interesting addition to your swing trading portfolio, specially now that it is ready to start trending up after being accumulated after enduring an extensive correction, now trading at a 40% discount from recent...
SGMO is forming a double bottom and could break out. RSI is oversold
SGMO has stochastic divergence on channel line support. Look for this to turn up more before getting in. Buy: 12.66 Target: 13.50 - 14.86 (6.64% - 17.38%)
Sangamo Daily Chart. Weekly Looking good NASDAQ:SGMO